Abstract

• The outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2/2019-nCoV) poses a serious threat to global public health and local economies.
• With the heightened interest of the potential use of chloroquine and hydroxychloroquine for the treatment of patients with SARS-CoV2 (COVID-19 or novel coronavirus)1 it may be prudent to reflect on the risks of therapy, particularly their cardiac toxicity.
• The purpose of this study was to investigate the propensity of hydroxychloroquine (HCQ) to cause bradycardia.